Testing a New Imaging Agent to Identify Cancer

NCT04692831 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HER-2 Positive Malignant Carcinoma of Breast
HER-2 Protein Overexpression
HER2-positive Metastatic Breast Cancer

Interventions

COMBINATION_PRODUCT: 89Zr-ss-pertuzumab PET/CT

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]